The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target

David M. Goldenberg _, Rhona Stein and Robert M. Sharkey

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:28989-29006. https://doi.org/10.18632/oncotarget.25615

Metrics: PDF 6109 views  |   HTML 23671 views  |   ?  


David M. Goldenberg1,2, Rhona Stein1 and Robert M. Sharkey1,3

1Center for Molecular Medicine and Immunology, Belleville, NJ, USA

2IBC Pharmaceuticals, Inc., Morris Plains, NJ, USA

3Immunomedics, Inc., Morris Plains, NJ, USA

Correspondence to:

David M. Goldenberg, email: [email protected]

Keywords: TROP-2; TACSTD2; sacituzumab govitecan; antibody-drug conjugates; immunotherapy

Received: April 30, 2018     Accepted: May 31, 2018     Published: June 22, 2018


TROP-2 is a glycoprotein first described as a surface marker of trophoblast cells, but subsequently shown to be increased in many solid cancers, with lower expression in certain normal tissues. It regulates cancer growth, invasion and spread by several signaling pathways, and has a role in stem cell biology and other diseases. This review summarizes TROP-2’s properties, especially in cancer, and particularly its role as a target for antibody-drug conjugates (ADC) or immunotherapy. When the irinotecan metabolite, SN-38, is conjugated to a humanized anti-TROP-2 antibody (sacituzumab govitecan), it shows potent broad anticancer activity in human cancer xenografts and in patients with advanced triple-negative breast, non-small cell and small-cell lung, as well as urothelial cancers.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 25615